Impact of a scientific presentation on community treatment patterns for primary breast cancer

Journal of the National Cancer Institute

Volumn 98, Issue 6, 2006, Pages 382-388

  Giordano, Sharon H ^a,b   Duan, Zhigang ^a,b   Kuo, Yong Fang ^a,b   Hortobagyi, Gabriel N ^a,b   Freeman, Jean ^a,b   Goodwin, James S ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; PACLITAXEL; TAXOID;

AGED; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER INCIDENCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE SURVEILLANCE; FEMALE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MASTECTOMY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; POPULATION DISTRIBUTION; PRIORITY JOURNAL; RISK ASSESSMENT; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TUMOR VOLUME; ADJUVANT CHEMOTHERAPY; BREAST TUMOR; CANCER REGISTRY; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG APPROVAL; EVIDENCE BASED MEDICINE; FOOD AND DRUG ADMINISTRATION; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; ORGANIZATION; PATHOLOGY; PRESCRIPTION; RANDOMIZED CONTROLLED TRIAL; STATISTICAL MODEL; STATISTICS; TIME; UNITED STATES;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CONGRESSES; DRUG APPROVAL; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; LOGISTIC MODELS; LYMPHATIC METASTASIS; MULTICENTER STUDIES; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PACLITAXEL; PHYSICIAN'S PRACTICE PATTERNS; PRESCRIPTIONS, DRUG; RANDOMIZED CONTROLLED TRIALS; SEER PROGRAM; TAXOIDS; TIME FACTORS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 33644943472     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djj090     Document Type: Article

References (34)

1. Jackevicius CA, Anderson GM, Leiter L, Tu JV. Use of the statins in patients after acute myocardial infarction: Does evidence change practice? Arch Intern Med 2001;161:183-8.
2. Stafford RS, Furberg CD, Finkelstein SN, Cockburn IM, Alehegn T, Ma J. Impact of clinical trial results on national trends in alpha-blocker prescribing, 1996-2002. JAMA 2004;291:54-62.
3. Haas JS, Kaplan CP, Gerstenberger EP, Kerlikowske K. Changes in the use of postmenopausal hormone therapy after the publication of clinical trial results. Ann Intern Med 2004;140:184-8.
4. Henderson IC, Berry D, Demetri GD, Cirrincione C, Goldstein LJ, Martino S, et al. Improved disease-free and overall survival from the addition of sequential paclitaxel but not from the escalation of doxorubicin dose in the adjuvant chemotherapy of patients with node-positive primary breast cancer. Proc ASCO 1998;17:101a.
5. Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S, et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003;21:976-83.
6. American Society of Clinical Oncology. ASCO Profile. Available at: http://www.asco.org. [Last accessed: January 4, 2005.]
7. Pollack A. Drug for advanced breast cancer is also found effective in early treatment. New York Times 1998 5/22/98; Sect. A14.
8. Burton T. Drug research alters standards for cancer care. Wall Street Journal 1998 5/19/98; Sect. B1.
9. Arnst C. Dispatches from the cancer front. Business Week 1998 6/1/98:146.
10. Inroads in battle against cancer. Maclean's 1998 6/1/98:52.
11. Marcus MB. Tracking a cancer cure. U.S. News and World Report 1998 6/1/ 98:52.
12. Nattinger AB, Hoffmann RG, Howell-Pelz A, Goodwin JS. Effect of Nancy Reagan's mastectomy on choice of surgery for breast cancer by US women. JAMA 1998;279:762-6.
13. Potosky AL, Riley GF, Lubitz JD, Mentnech RM, Kessler LG. Potential for cancer related health services research using a linked Medicare-tumor registry database. Med Care 1993;31:732-48.
14. Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI, et al. Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol 2002;20:3628-36.
15. Marsh L, Cormier D. Spline regression models. Thousand Oaks (CA): Sage; 2001.
16. Marsh L, Mcglynn M, Chakraborty D. Interpreting complex nonlinear models. Proceedings of SAS User's Group International 1994;19: 1185-9.
17. Marsh L. Estimating the number and location of knots in spline regression. J Appl Bus Res 1986;3:60-70.
18. Hosmer D, Lemeshow S. Applied logistic regression. New York (NY): John Wiley & Sons; 2000.
19. Zhang J, Yu K. What's the relative risk: A method of correcting the odds ratio in cohort studies of common outcomes. JAMA 1998;280:1690-1.
20. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, et al. Cancer statistics, 2004. CA Cancer J Clin 2004;54:8-29.
21. National Institutes of Health Consensus Development Conference statement: Adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst Monogr 2001;30:5-15.
22. Martin M, Pienkowski T, Mackey J, Pawlicki M, Guastalla JP, Weaver C, et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005;352:2302-13.
23. Mamounas EP, Bryant J, Lembersky B, Fehrenbacher L, Sedlacek SM, Fisher B, et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: Results from NSABP B-28. J Clin Oncol 2005;23:3686-96.
24. Heys SD, Hutcheon AW, Sarkar TK, Ogston KN, Miller ID, Payne S, et al. Neoadjuvant docetaxel in breast cancer: 3-year survival results from the Aberdeen trial. Clin Breast Cancer 2002;3 Suppl 2:S69-74.
25. Clinical Practice Guidelines in Oncology. Breast cancer. Available at: http://www.nccn.org/professionals/physician_gls/default.asp. [Last accessed: February 9, 2006.]
26. Polychemotherapy for early breast cancer: An overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998;352:930-42.
27. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.[see comment]. N Engl J Med 2003;349:1793-802.
28. Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer.[see comment]. N Engl J Med 2004;350:1081-92.
29. Pilepich M, Caplan R, Byhardt R, Lawton C, Gallagher M, Mesic J, et al. Phase III trial of androgen suppression using goserelin in unfavorable prognosis carcinoma of the prostate treated with defi nitive radiotherapy (RTOG 85-31). Proc ASCO 1995;14:239.
30. Greenfi eld S, Blanco DM, Elashoff RM, Ganz PA. Patterns of care related to age of breast cancer patients. JAMA 1987; 257: 2766-70.
31. Goodwin JS, Hunt WC, Samet JM. Determinants of cancer therapy in elderly patients. Cancer 1993; 72: 594-601.
32. Silliman RA, Guadagnoli E, Weitberg AB, Mor V. Age as a predictor of diagnostic and initial treatment intensity in newly diagnosed breast cancer patients. J Gerontol 1989;44:M46-50.
33. Samet J, Hunt WC, Key C, Humble CG, Goodwin JS. Choice of cancer therapy varies with age of patient. JAMA 1986;255:3385-90.
34. Mandelblatt JS, Hadley J, Kerner JF, Schulman KA, Gold K, Dunmore-Griffith J, et al. Patterns of breast carcinoma treatment in older women: Patient preference and clinical and physical infl uences. Cancer 2000;89: 561-73.